Tirzepatide, 5-Amino-1MQ, and NAD+ nasal spray: what the evidence actually says

What did @genxshopfinds76 actually say?

Jen, who identifies as a nurse practitioner, promoted a three-compound stack for fat loss: tirzepatide, 5-amino-1MQ, and NAD+ nasal spray. She described this combination as producing appetite suppression, cellular fat burning, and sustained energy without muscle loss. Her pitch was direct: "lose fat, keep your muscle and not feel like a zombie while doing it."

She characterized tirzepatide as "a metabolic reset," called 5-amino-1MQ "your cellular fat burner" that works "inside the fat cell to shrink it," and positioned NAD+ nasal spray as the solution to low energy on GLP-1 therapy. She closed by offering consultations to Ohio residents, which establishes this as promotional content tied to her practice, not just general education.

Does the science back this up?

Tirzepatide has the strongest evidence base of the three. The other two compounds are in much earlier stages of human research, and combining all three in a clinical stack is not supported by any published trial.

Tirzepatide's efficacy is well-documented. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed up to 20.9% body weight reduction in adults with obesity over 72 weeks, with significant improvements in metabolic markers. That "metabolic reset" framing is actually not far off from how researchers describe the drug's dual GIP and GLP-1 receptor agonism.

5-amino-1MQ is a different story. It inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that regulates fat cell metabolism. Early animal studies, including Neelakantan et al. (2019, Nature Communications), showed fat mass reduction in mice without muscle loss. Human data is essentially nonexistent at this point. Calling it a validated "cellular fat burner" for humans is a significant leap.

NAD+ nasal spray has almost no published clinical data as a delivery mechanism. General NAD+ precursor research (Yoshino et al., 2021, Science) suggests potential metabolic benefits, but the nasal spray format is not the same as oral NMN or NR, and no peer-reviewed study has tested it in GLP-1 users specifically.

What did they get wrong (or right)?

Jen got tirzepatide broadly right. She overstated 5-amino-1MQ. She made an unsupported leap on NAD+ nasal spray.

Credit where it is due: tirzepatide does meaningfully reduce "food noise" (a term researchers like Tahrani use to describe intrusive hunger cognition), and its effects on blood sugar are clinically established. Her description of it as an MVP is defensible given current evidence.

The 5-amino-1MQ claim that it works "inside the fat cell to shrink it" is derived from rodent data. Presenting this to a 34,000-viewer audience as a reliable fat loss tool in humans is misleading, not because the mechanism is implausible, but because the human evidence simply does not exist yet.

The NAD+ nasal spray framing is the weakest link. Saying it "supports mitochondria so you feel sharp, focused, energetic" treats a largely unproven delivery method as if it were an established intervention. The mitochondrial NAD+ connection is real in preclinical work, but the jump to nasal spray clinical outcomes is not supported.

• Tirzepatide claims: mostly accurate
• 5-amino-1MQ claims: misleading due to extrapolation from animal data
• NAD+ nasal spray claims: unverifiable with current human evidence

What should you actually know?

This stack is not a protocol with a published evidence base. It is a combination assembled from compounds at very different stages of human research, marketed as a coherent system.

Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound), and it carries real side effects including nausea, pancreatitis risk, and potential thyroid concerns noted in prescribing information. It requires medical supervision and is not appropriate for everyone. The compounded versions circulating in telehealth markets are not equivalent to FDA-approved branded products, and their quality varies by pharmacy.

5-amino-1MQ is not FDA-approved for any indication. Anyone using it is participating in what amounts to an uncontrolled human experiment. That may be a risk some people accept, but they deserve to know that is what they are doing.

If you are considering GLP-1 therapy, a board-certified obesity medicine physician or endocrinologist is the appropriate starting point, not a TikTok consult funnel, however well-intentioned the creator may be.